-
07:53:56 AM

ALPN Stock News

03/23/23 4:05 PM
Nasdaq : ALPN
earnings
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022. Povetacicept looks to be the first true dual inhibitor of both the BAFF and...
RHEA-AI
neutral
03/20/23 4:30 PM
Nasdaq : ALPN
conferencesclinical trial
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology& Therapeutics Annual Meeting and at the International Society of Nephrology World Congress of Nephrology.
RHEA-AI
neutral
03/16/23 5:30 PM
Nasdaq : ALPN
conferencesclinical trial
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster with an oral presentation at the American Academy of Dermatology Annual Meeting, highlighting clinical data from RUBY-1, a phase 1 healthy volunteer study of...
RHEA-AI
neutral
11/22/22 4:15 PM
Nasdaq : ALPN
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will participate in a fireside chat at the 5 th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022, at 12:35 p.m. ET/ 9:35 a.m. PT.
RHEA-AI
neutral
11/03/22 4:15 PM
Nasdaq : ALPN
clinical trial
Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today presented a poster at the American Society of Nephrology Kidney Week 2022 Meeting highlighting updated clinical data from RUBY-1, a phase 1 healthy volunteer study of ALPN-303, a dual B...
RHEA-AI
neutral